The ACE Follow-up Study
Primary Purpose
Obesity
Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
ACE Stapler
Sponsored by

About this trial
This is an interventional treatment trial for Obesity focused on measuring Weight Loss, Trans-oral Endoscopic Procedure, Gastric Plication
Eligibility Criteria
Inclusion Criteria:
- Subject, male or female, is age 18 to 50 years of age.
- Subject must be able to understand and be willing to sign an informed consent document.
- Subject must be willing and able to participate in all aspects of the study and agree to comply with all study requirements for the duration of the study. This includes availability of reliable transportation and sufficient time to attend all follow-up visits.
- Subject has a BMI of 40 - 45 or 30 to 39.9 plus one or more co-morbid diseases expected to improve with weight loss, including but not limited to hypertension, dyslipidemia, obstructive sleep apnea, or diabetes mellitus.
- Subject must be fully ambulatory, without chronic reliance on walking aids such as crutches, walkers or a wheelchair.
- Subject must be of sufficient and stable medical health, as evaluated by the Principal Investigator.
- Subject must have a primary care physician that will manage the subject for any co-morbid conditions throughout the study.
- Subject must have failed standard obesity therapy of diet, exercise, behavior modification, and pharmacologic agents either alone or in combination, as assessed by an interview with a member of the study team at baseline.
- Subject agrees to refrain from any type of reconstructive surgery that may affect body weight such as mammoplasty or abdominal lipoplasty or liposuction, during the trial.
Exclusion Criteria:
- Subject has history of/or signs and/or symptoms of gastro-duodenal ulcer disease.
- Subject has poorly controlled diabetes as indicated by the lack of stable diabetes medications and doses over the last month, or has a history of diabetes for greater than 10 years.
- Subject has had significant weight loss in the last 3 months, or between baseline and the study procedure.
- Subject has a history or is diagnosed with eating disorders.
- Subject has history of peptic ulcer and tests positive for H. pylori, unless treated before the procedure.
- Subject has symptomatic congestive heart failure, cardiac arrhythmia or unstable coronary artery disease.
- Subject has pre-existing respiratory disease such as chronic obstructive pulmonary disease (COPD), pneumonia or cancer.
- Subject has significant esophageal disease including Zenker's diverticulum, grade 3-4 reflux esophagitis, stricture, Barrett's esophagus, esophageal cancer, esophageal diverticulum, dysphagia, achalasia, or symptoms of dysmotility.
- Subject is observed during EGD to have heavily scarred, malignant or poor quality/friable tissue in areas of the stomach where plications are to be placed.
Sites / Locations
- Hospital Aleman / Programa de Unidades Bariátricas
- Hospital Italiano de Mendoza / Clinica Quirugica S. A.
- University Institute of Cardiology and Pulmonary Medicine of Quebec
- Tel-Aviv Sourasky Medical Center
- Amsterdam Medical Center
- University Hospital Maastricht
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
ACE procedure
Arm Description
ACE procedure for the treatment of obesity
Outcomes
Primary Outcome Measures
Safety
The primary safety analysis will assess the occurrence and procedure relatedness of the following events:
Adverse Events (AE)
Adverse Device Effects (ADE)
Serious Adverse Events (SAE)
Unanticipated Adverse Device Effects (UADE)
Secondary Outcome Measures
Percent excess weight loss
Percent excess weight loss (%EWL), defined as: (preoperative weight-current weight)/(preoperative weight - ideal weight) *100, where ideal weight is the weight that would correspond to a BMI of 25 based on the subject's height.
Relative to weight at the procedure visit.
Total weight lost (kg) and percent weight lost
Relative to weight at the procedure visit.
Change in Body Mass Index (BMI) and percent change in BMI
Relative to BMI at the procedure visit.
Change in waist circumference
Relative to to waist circumference at the procedure visit.
Improvement in co-morbid disease(s)
Including but not limited to, improvement in vital signs and/or laboratory values.
Changes in Quality of Life
As reported on the SF-36 Quality of LIfe Questionnaire.
Changes in Feelings of Satiety
As reported on the TFEQ-R18 Three Factor Eating Questionnaire.
Full Information
NCT ID
NCT01429194
First Posted
September 2, 2011
Last Updated
June 15, 2015
Sponsor
Boston Scientific Corporation
1. Study Identification
Unique Protocol Identification Number
NCT01429194
Brief Title
The ACE Follow-up Study
Official Title
Continuation of Follow-up for Patients Who Were Previously Enrolled in the Clinical Study: "Open Prospective Study to Evaluate the Safety and Preliminary Effectiveness of the BaroSense ACE Stapler for the Treatment of Obesity - (Protocol 11-03)."
Study Type
Interventional
2. Study Status
Record Verification Date
June 2015
Overall Recruitment Status
Completed
Study Start Date
April 2012 (undefined)
Primary Completion Date
February 2015 (Actual)
Study Completion Date
February 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boston Scientific Corporation
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The Articulating Circular Endoscopic (ACE) Stapler is an investigational system using endoscopic guidance to trans-orally place plications in the stomach in obese subjects to reduce volume and expansion of the fundus and greater curve to abate hunger as part of a supervised weight reduction program.
The primary objective of this study is to perform an evaluation of the safety of the plication procedure.
The secondary objective of this study is to evaluate the preliminary efficacy of the ACE Stapler for the treatment of obesity over a 24 month follow-up period.
Detailed Description
This study was originally sponsored by BaroSense, Inc (protocol 11-03). 69 subjects were enrolled and treated as part of the study at 6 centers in 4 countries outside the United States. On April 30, 2013 BaroSense Inc went out of business and the study was terminated with all participating centers' Ethics Committees. At the point of study termination, all patients were in the middle of post procedure follow-up.
Boston Scientific has since acquired the technology and study and will re-initiate follow-up to 24 months in order to collect data to support the original safety and efficacy endpoints of the protocol. Only the 69 subjects previously enrolled and treated in BaroSense's protocol 11-03 will be eligible for participation in the Boston Scientific continued follow-up study ("The ACE Follow-up Study" protocol 90891629). The Boston Scientific protocol will be approved by participating centers' Ethics Committees and patients who choose to participate in The ACE Follow-up Study will need to sign a new, Ethics Committee Approved, informed consent form.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Weight Loss, Trans-oral Endoscopic Procedure, Gastric Plication
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
69 (Actual)
8. Arms, Groups, and Interventions
Arm Title
ACE procedure
Arm Type
Experimental
Arm Description
ACE procedure for the treatment of obesity
Intervention Type
Procedure
Intervention Name(s)
ACE Stapler
Intervention Description
The ACE Stapler is used endoscopically, and incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
Primary Outcome Measure Information:
Title
Safety
Description
The primary safety analysis will assess the occurrence and procedure relatedness of the following events:
Adverse Events (AE)
Adverse Device Effects (ADE)
Serious Adverse Events (SAE)
Unanticipated Adverse Device Effects (UADE)
Time Frame
Enrollment through 24 months post-procedure.
Secondary Outcome Measure Information:
Title
Percent excess weight loss
Description
Percent excess weight loss (%EWL), defined as: (preoperative weight-current weight)/(preoperative weight - ideal weight) *100, where ideal weight is the weight that would correspond to a BMI of 25 based on the subject's height.
Relative to weight at the procedure visit.
Time Frame
Procedure through 24 months post-procedure
Title
Total weight lost (kg) and percent weight lost
Description
Relative to weight at the procedure visit.
Time Frame
Procedure through 24 months post-procedure
Title
Change in Body Mass Index (BMI) and percent change in BMI
Description
Relative to BMI at the procedure visit.
Time Frame
Procedure through 24 months post-procedure
Title
Change in waist circumference
Description
Relative to to waist circumference at the procedure visit.
Time Frame
Procedure through 24 months post-procedure
Title
Improvement in co-morbid disease(s)
Description
Including but not limited to, improvement in vital signs and/or laboratory values.
Time Frame
Enrollment through 24 months post-procedure
Title
Changes in Quality of Life
Description
As reported on the SF-36 Quality of LIfe Questionnaire.
Time Frame
Enrollment through 24 months post-procedure
Title
Changes in Feelings of Satiety
Description
As reported on the TFEQ-R18 Three Factor Eating Questionnaire.
Time Frame
Enrollment through 24 months post-procedure
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject, male or female, is age 18 to 50 years of age.
Subject must be able to understand and be willing to sign an informed consent document.
Subject must be willing and able to participate in all aspects of the study and agree to comply with all study requirements for the duration of the study. This includes availability of reliable transportation and sufficient time to attend all follow-up visits.
Subject has a BMI of 40 - 45 or 30 to 39.9 plus one or more co-morbid diseases expected to improve with weight loss, including but not limited to hypertension, dyslipidemia, obstructive sleep apnea, or diabetes mellitus.
Subject must be fully ambulatory, without chronic reliance on walking aids such as crutches, walkers or a wheelchair.
Subject must be of sufficient and stable medical health, as evaluated by the Principal Investigator.
Subject must have a primary care physician that will manage the subject for any co-morbid conditions throughout the study.
Subject must have failed standard obesity therapy of diet, exercise, behavior modification, and pharmacologic agents either alone or in combination, as assessed by an interview with a member of the study team at baseline.
Subject agrees to refrain from any type of reconstructive surgery that may affect body weight such as mammoplasty or abdominal lipoplasty or liposuction, during the trial.
Exclusion Criteria:
Subject has history of/or signs and/or symptoms of gastro-duodenal ulcer disease.
Subject has poorly controlled diabetes as indicated by the lack of stable diabetes medications and doses over the last month, or has a history of diabetes for greater than 10 years.
Subject has had significant weight loss in the last 3 months, or between baseline and the study procedure.
Subject has a history or is diagnosed with eating disorders.
Subject has history of peptic ulcer and tests positive for H. pylori, unless treated before the procedure.
Subject has symptomatic congestive heart failure, cardiac arrhythmia or unstable coronary artery disease.
Subject has pre-existing respiratory disease such as chronic obstructive pulmonary disease (COPD), pneumonia or cancer.
Subject has significant esophageal disease including Zenker's diverticulum, grade 3-4 reflux esophagitis, stricture, Barrett's esophagus, esophageal cancer, esophageal diverticulum, dysphagia, achalasia, or symptoms of dysmotility.
Subject is observed during EGD to have heavily scarred, malignant or poor quality/friable tissue in areas of the stomach where plications are to be placed.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Simon Biron, MD
Organizational Affiliation
University Institute of Cardiology and Pulmonary Medicine of Quebec
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Aleman / Programa de Unidades Bariátricas
City
Autonoma de Bueno Aires
ZIP/Postal Code
CP 1118
Country
Argentina
Facility Name
Hospital Italiano de Mendoza / Clinica Quirugica S. A.
City
Mendoza
ZIP/Postal Code
290
Country
Argentina
Facility Name
University Institute of Cardiology and Pulmonary Medicine of Quebec
City
Quebec
ZIP/Postal Code
G1V 4G5
Country
Canada
Facility Name
Tel-Aviv Sourasky Medical Center
City
Tel-Aviv
ZIP/Postal Code
64234
Country
Israel
Facility Name
Amsterdam Medical Center
City
Amsterdam
ZIP/Postal Code
110AZ
Country
Netherlands
Facility Name
University Hospital Maastricht
City
Maastricht
ZIP/Postal Code
6202
Country
Netherlands
12. IPD Sharing Statement
Citations:
PubMed Identifier
25085333
Citation
Verlaan T, Paulus GF, Mathus-Vliegen EM, Veldhuyzen EA, Conchillo JM, Bouvy ND, Fockens P. Endoscopic gastric volume reduction with a novel articulating plication device is safe and effective in the treatment of obesity (with video). Gastrointest Endosc. 2015 Feb;81(2):312-20. doi: 10.1016/j.gie.2014.06.017. Epub 2014 Jul 29.
Results Reference
derived
Learn more about this trial
The ACE Follow-up Study
We'll reach out to this number within 24 hrs